Two of our partnering team

Learn more about our recent partnerships

Amgen logo


AstraZeneca, with its biologics arm MedImmune, entered into a global collaboration with Amgen in April 2012 to co-develop and commercialize five monoclonal antibodies from Amgen’s clinical portfolio across a range of inflammatory indications. The number of molecules and indications involved make it one of the biggest peer-to-peer deals ever completed within the industry and sets a benchmark for other companies pursuing similar deal structures.

Read case study (PDF 408kb)
Bristol-Myers Squibb logo

Bristol-Myers Squibb

Further to Bristol-Myers Squibb acquisition of Amylin Pharmaceuticals in August 2012, our existing collaboration with Bristol-Myers Squibb was expanded to include the development and commercialisation of Amylin’s portfolio of diabetes products. The addition of these products strengthens our worldwide diabetes alliance, creating a broader disease management platform for patients, physicians and payers.

Read case study (PDF 335kb)
Hutchison Medi Pharma logo

Hutchison Medi Pharma

We entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504) with Hutchison Medi Pharma in December 2011.

Read case study (PDF 256kb)
Download our brochure

Download your comprehensive guide to partnering with us.